Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
ARCH Venture Fund VII and affiliated reporting persons amend a Schedule 13G/A to report beneficial ownership of 5,725,045 shares of Common Stock of 908 Devices Inc. The filing states the Record Shares are held by ARCH Venture Fund VII as of March 31, 2026. The percentage on the cover pages is 15.1% for the reporting entities and 15.3% for Keith Crandell, with the latter reflecting vested options, 57,794 vested option shares, 25,291 RSUs and 1,086 options vesting within sixty days. The percentage figures are calculated using 37,813,621 shares outstanding as of May 4, 2026, per the issuer’s Form 10-Q.
AWM Investment Company, Inc., a 10% owner of 908 Devices Inc., reported an indirect open-market sale of 5,000 shares of Common Stock at a weighted average price of $8.2514 per share on May 11, 2026.
The shares are held through a limited partnership, and AWM reports indirect ownership. After this transaction, entities advised by AWM collectively held 5,116,715 shares of 908 Devices Common Stock. AWM and its principals disclaim beneficial ownership beyond their pecuniary interest.
908 Devices Inc. senior vice president of sales and product marketing John Kenneweg sold 18,255 shares of Common Stock in an open-market transaction on May 8, 2026 at a weighted average price of $8.11 per share. The sales occurred at prices ranging from $7.99 to $8.20. After these transactions, he directly owns 57,784 shares of 908 Devices Common Stock.
AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc., reported indirect open-market sales of the company’s common stock through a limited partnership. Across four transactions on May 6–8, AWM-related funds sold a total of 78,209 shares at prices around $8 per share.
Individual trades included 5,000 shares at $8.00, 57,365 shares at $8.0564, 12,819 shares at $8.2042, and 3,025 shares at $8.20. After these sales, AWM, as investment adviser to several funds, reports indirect ownership of 5,121,715 shares and disclaims beneficial ownership except for its pecuniary interest.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock issued as Performance Stock Units (PSUs), listing 18,255 units. The filing shows a reported sale by John Kenneweg of 7,787 PSUs on 05/01/2026 for $53,185.21.
908 Devices Inc. director Christopher D. Brown sold shares in a planned transaction. On May 6, 2026, he completed an open-market sale of 20,000 shares of common stock at a weighted average price of $7.23 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
After this sale, Brown directly holds 925,559 shares of 908 Devices common stock. The shares were sold in multiple trades at prices ranging from $7.00 to $7.49 per share.
908 Devices reported Q1 2026 revenue from continuing operations of $13.4 million, up from $11.8 million a year earlier, driven mainly by higher handheld device sales. Recurring revenue, including consumables, accessories and services, represented 30% of total revenue.
The company posted a net loss from continuing operations of $12.0 million (or $0.32 per share), compared with a loss of $9.8 million in Q1 2025, which had been offset at the time by a large gain from the prior-year sale of its Desktop Portfolio.
As of March 31, 2026, 908 Devices held $67.6 million in cash and cash equivalents and $44.2 million in marketable securities, and believes these resources plus revenue will fund operations for at least 12 months. Deferred revenue totaled $18.5 million, reflecting future product and service obligations, and a $20 million undrawn revolving credit facility was put in place in March 2026.
The RedWave acquisition performance targets were achieved, increasing contingent consideration to $22.4 million. After quarter-end, the company agreed to acquire Switzerland-based NIRLAB for headline consideration of $15.0 million in cash and stock to expand its material identification capabilities.
908 Devices reported Q1 2026 revenue from continuing operations of $13.4 million, up from $11.8 million a year earlier, driven mainly by higher handheld device sales. Recurring revenue, including consumables, accessories and services, represented 30% of total revenue.
The company posted a net loss from continuing operations of $12.0 million (or $0.32 per share), compared with a loss of $9.8 million in Q1 2025, which had been offset at the time by a large gain from the prior-year sale of its Desktop Portfolio.
As of March 31, 2026, 908 Devices held $67.6 million in cash and cash equivalents and $44.2 million in marketable securities, and believes these resources plus revenue will fund operations for at least 12 months. Deferred revenue totaled $18.5 million, reflecting future product and service obligations, and a $20 million undrawn revolving credit facility was put in place in March 2026.
The RedWave acquisition performance targets were achieved, increasing contingent consideration to $22.4 million. After quarter-end, the company agreed to acquire Switzerland-based NIRLAB for headline consideration of $15.0 million in cash and stock to expand its material identification capabilities.
908 Devices Inc. completed the acquisition of Swiss-based NIRLAB, a near‑infrared spectroscopy company, for a preliminary $15 million, split between $13 million in cash and 293,368 shares of common stock, plus up to $8 million in stock earn‑outs tied to revenue milestones through December 31, 2027.
Q1 2026 revenue was $13.4 million, up 14% year over year, with growth in both mass spectrometry and FTIR products. GAAP gross margin improved to 51%, and adjusted gross margin to 57%, while adjusted EBITDA loss narrowed to $2.5 million. The company reported a continuing-operations net loss of about $12.0 million, supported by $111.7 million of cash, cash equivalents and marketable securities and no debt as of March 31, 2026.
The installed base grew 23% to 3,903 devices, with recurring revenue at 30% of total. Management raised full‑year 2026 revenue guidance to a range of $67.0–$70.0 million, representing 19%–25% growth versus 2025.
908 Devices Inc. completed the acquisition of Swiss-based NIRLAB, a near‑infrared spectroscopy company, for a preliminary $15 million, split between $13 million in cash and 293,368 shares of common stock, plus up to $8 million in stock earn‑outs tied to revenue milestones through December 31, 2027.
Q1 2026 revenue was $13.4 million, up 14% year over year, with growth in both mass spectrometry and FTIR products. GAAP gross margin improved to 51%, and adjusted gross margin to 57%, while adjusted EBITDA loss narrowed to $2.5 million. The company reported a continuing-operations net loss of about $12.0 million, supported by $111.7 million of cash, cash equivalents and marketable securities and no debt as of March 31, 2026.
The installed base grew 23% to 3,903 devices, with recurring revenue at 30% of total. Management raised full‑year 2026 revenue guidance to a range of $67.0–$70.0 million, representing 19%–25% growth versus 2025.
908 Devices Inc. SVP John Kenneweg reported a routine equity compensation event involving vested performance stock units (PSUs) and a related tax sale. On May 1, 2026, 26,042 PSUs vested and were converted into 26,042 shares of Common Stock. To cover tax withholding obligations from this vesting, 7,787 shares of Common Stock were sold in an open-market “sell to cover” transaction at $6.83 per share, a sale mandated by the company’s election and described as non-discretionary for the insider. Following these transactions, Kenneweg directly holds 76,039 shares of Common Stock, and all of the reported PSUs have been fully settled.
Kenneweg John reported acquisition or exercise transactions in this Form 4 filing.
908 Devices Inc. reported that SVP of Sales & Product Marketing John Kenneweg received a grant of 26,042 Performance Stock Units. Each unit represents a contingent right to receive one share of Common Stock with a par value of $0.001 when it vests.
The compensation committee certified achievement of the required performance metrics and goals on April 28, 2026, and the PSUs are scheduled to vest on May 1, 2026 in accordance with their terms. The PSUs have no expiration date, and this filing reflects a compensation-related equity award rather than an open-market trade.